HIV-1 recombinant gp160 vaccine induced antibodies in serum and saliva. The NIAID AIDS Vaccine Clinical Trials Network.

Abstract	As part of a phase I safety and immunogenicity trial of a vaccinia-expressed HIV-1 recombinant gp160 (rgp160) candidate vaccine, we measured serum and saliva antibody responses in low risk, uninfected volunteers. Six healthy adult volunteers received 50 micrograms doses of rgp160 vaccine adjuvanted in alum and deoxycholate at months 0, 1, 6, and 12. A 200 micrograms rgp160 immunization was given to four volunteers at 18 months. The vaccine induced anti-envelope glycoprotein IgG and IgA serum antibodies in all six volunteers. Saliva antibodies to envelope glycoprotein appeared in some volunteers at certain timepoints. Three volunteers appeared to transiently develop vaccine-induced secretory IgA antibody to envelope glycoprotein in whole saliva.
Authors	G J Gorse, J H Rogers, J E Perry, F K Newman, S E Frey, G B Patel, R B Belshe
Journal	Vaccine (Vaccine) Vol. 13 Issue 2 Pg. 209-14 (Feb 1995) ISSN: 0264-410X [Print] Netherlands
PMID	7625118 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References	AIDS Vaccines Adjuvants, Immunologic Alum Compounds Gene Products, env HIV Antibodies HIV Envelope Protein gp160 Immunoglobulin A Immunoglobulin G Protein Precursors Vaccines, Synthetic Deoxycholic Acid aluminum sulfate
Topics	AIDS Vaccines (administration & dosage, pharmacology) Adjuvants, Immunologic (administration & dosage, pharmacology) Adolescent Adult Alum Compounds (administration & dosage) Deoxycholic Acid (administration & dosage) Gene Products, env (immunology) HIV Antibodies (biosynthesis, blood) HIV Envelope Protein gp160 HIV-1 (immunology) Humans Immunoglobulin A (biosynthesis, blood) Immunoglobulin G (biosynthesis, blood) Middle Aged Protein Precursors (immunology) Saliva (immunology, virology) Vaccines, Synthetic (administration & dosage, pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!